89bio price target raised to $38 from $25 at UBS, says shares ‘undervalued’
UBS raised the firm’s price target on 89bio (ETNB) to $38 from $25 and keeps a Buy rating on the shares. Akero Therapeutics (AKRO) reported ...
Akero Therapeutics price target raised to $109 from $42 at UBS
UBS raised the firm’s price target on Akero Therapeutics (AKRO) to $109 from $42 and keeps a Buy rating on the shares. Akero reported “strong” ...
North American Morning Briefing: Investors in -2-
A midair collision between an American Airlines flight and an Army helicopter over the Potomac River killed all 67 people on the two aircraft, officials said Thursday, leaving investigators to piece ...